Gt Biopharma, Inc. (NASDAQ:GTBP)

Gt Biopharma (NASDAQ:GTBP) ($11.26, $237.8m market cap) a clinical stage immunology company  announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.

Anthony J. Cataldo, GT Biopharma's Chairman and Chief Executive Officer, commented: 

"We are pleased to report our GTB-5550 TriKE™ has passed this important development milestone, and demonstrated effectiveness in promoting redirected and target-specific killing by NK cells."

Gt Biopharma (NASDAQ:GTBP) ($15.1, $428.7m market cap) a clinical stage immunology company announced an update on the commencement of the phase 2 clinical trial for GTB-3550 Trike monotherapy. 

“We believe GTB-3550 TriKE™ sets a new standard for NK cell engager therapies due to the incorporation of interleukin 15 (IL-15) directly in the protein backbone," said Anthony J. Cataldo, GT Biopharma's Chairman and Chief Executive Officer.  "The flexibility and versatility of our TriKE™ platform allows us to change the cancer cell targeting mechanism of TriKE™ to attack different cancers while maintaining the core NK cell activation, proliferation and persistence